Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold

Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold

The constitutively active tyrosine kinase BCR-ABL is the underlying cause of chronic myeloid leukemia (CML). Current CML treatments rely on the long-term use of tyrosine kinase inhibitors (TKIs), which target the ATP binding site of BCR-ABL. Over the course of treatment, 20–30% of CML patients devel...

Full description

Bibliographic Details
Main Authors: Huang, Yen-Hua, Henriques, Sónia T., Wang, Conan K., Thorstholm, Louise, Daly, Norelle L., Kaas, Quentin, Craik, David J.
Format: Online
Language:English
Published: Nature Publishing Group 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532999/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532999/

Similar Items